Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.40
-0.2200-6.08%
Volume:192.04K
Turnover:662.90K
Market Cap:106.39M
PE:-0.82
High:3.58
Open:3.58
Low:3.38
Close:3.62
52wk High:49.25
52wk Low:3.38
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.75
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.49
PE(LYR):-1.19

Loading ...

CAMP4 Therapeutics Initiated at Outperform by Oppenheimer

Dow Jones
·
Oct 06

EXACT Therapeutics Issues Detailed Guidance Ahead of Euronext Growth Delisting

TIPRANKS
·
Oct 05

Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026

GlobeNewswire
·
Oct 05

Aprea Therapeutics to Present at October Conferences

GlobeNewswire
·
Oct 05

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

GlobeNewswire
·
Oct 05

Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)

GlobeNewswire
·
Oct 05

Monte Rosa Therapeutics Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 05

Oppenheimer Initiates Coverage on CAMP4 Therapeutics With Outperform Rating, $15 Price Target

MT Newswires Live
·
Oct 05

AstraZeneca completes $2B equity investment in Summit Therapeutics

TIPRANKS
·
Oct 05

Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

GlobeNewswire
·
Oct 05

Crispr Therapeutics: Favorable Early zugo-cel Data in Systemic Sclerosis Support Buy Rating; $82 Price Target Reiterated

TIPRANKS
·
Oct 05

Sarepta Therapeutics: ELEVIDYS Data and Revenue Trends Support Continued Sell Rating with Unchanged $5 Price Target

TIPRANKS
·
Oct 05

Percheron Therapeutics Plans Issue of 75 Million Performance Restricted Stock Units

TIPRANKS
·
Oct 05

Chimeric Therapeutics Discloses Final Director Interest as Lesley Russell Departs Board

TIPRANKS
·
Oct 05

Chimeric Therapeutics Announces Departure of Director Without Shareholdings

TIPRANKS
·
Oct 05

Chimeric Therapeutics Names New Director, Grants 500,000 Options

TIPRANKS
·
Oct 05

ASX Preview: Australian Shares to Rise as Oil Climbs on Saudi Attacks; CSL Partners With Alentis Therapeutics to Develop Rare Kidney, Liver Disease Drug

MT Newswires Live
·
Oct 05

Percheron Therapeutics Names New CEO to Drive Oncology Strategy and Investor Outreach

TIPRANKS
·
Oct 05

Monte Rosa Therapeutics Stock In Focus After Phase 1 Data Win

Simply Wall St.
·
Oct 03

Neurosense Therapeutics Receives Nasdaq Listing Compliance Notice

MT Newswires Live
·
Oct 03